Autosomal dominant tubulointerstitial kidney disease (ADTKD)  is a group of inherited kidney conditions that pass from parent to child in an autosomal-dominant pattern (each child has a 50% chance to inherit). The kidneys slowly lose working units in the tubules and the surrounding tissue (the “tubulointerstitium”). Over many years, this causes chronic kidney disease and sometimes kidney failure. Early urine tests are often “bland,” meaning little or no blood or protein is seen. Many people develop high blood pressure, anemia, and in some subtypes, gout due to high uric acid. A new kidney transplant is usually curative because the disease does not come back in the transplanted kidney. NCBI+1

Autosomal dominant interstitial kidney disease (ADTKD) is a group of inherited kidney conditions. “Autosomal dominant” means a person needs only one changed copy of the gene to be affected, and it often runs strongly in families. “Tubulointerstitial” means the main damage happens in the tubules (the tiny pipes that recycle water, salts, and acid–base chemicals) and in the interstitial space (the tissue between those tubules). Over many years, the kidneys scar slowly (fibrosis). Kidney function falls little by little, and some people eventually reach kidney failure as adults. Urine tests are often “bland” (not much blood or protein), which can make the disease easy to miss without a strong family history. Gout and high uric acid are especially common in some genetic types. Kireports+2PMC+2

Common gene subtypes include UMOD, MUC1, REN, HNF1B, and rarer SEC61A1 and DNAJB11. These genes affect proteins important for tubule health; mutations slowly injure tubules, leading to scarring. In ADTKD-UMOD, gout can show up in adolescence; in ADTKD-MUC1, the main problem is gradual kidney decline; in ADTKD-REN, anemia, acidosis, and high potassium may appear early. Genetic testing confirms the diagnosis. OUP Academic+3NCBI+3NCBI+3

Other names

Doctors used several older names before the ADTKD term became standard. You may still see these in charts or older articles:

• Medullary Cystic Kidney Disease (MCKD) type 1 and type 2

• Familial Juvenile Hyperuricemic Nephropathy (FJHN)

• Uromodulin-Associated Kidney Disease (UAKD) or UMOD-associated kidney disease
  These refer to the same general family of disorders and map to specific gene forms of ADTKD. The KDIGO consensus recommended using the unified name “ADTKD,” plus the gene name (for example, ADTKD-UMOD), to reduce confusion. KDIGO+1

Types

ADTKD is named by the gene with the disease-causing change. The most established subtypes are:

1. ADTKD-UMOD (uromodulin gene) – very common; high uric acid and gout are typical; kidney failure can occur in mid-to-late adulthood. PMC+1

2. ADTKD-MUC1 (mucin-1 gene) – used to be called MCKD type 1; slow chronic kidney disease (CKD) with very little else outside the kidney. NCBI

3. ADTKD-REN (renin gene) – may show early anemia, low blood pressure, salt-wasting, and periodic kidney function dips, especially in childhood. PubMed

4. ADTKD-HNF1B – can include kidney cysts and non-kidney features (such as diabetes or congenital urinary tract differences). OUP Academic

5. ADTKD-SEC61A1 – rarer, but reported. OUP Academic

6. DNAJB11-related disease – considered “atypical” ADTKD in some reports (overlaps with cystic phenotypes). OUP Academic

7. APOA4 – very rare families reported more recently. ScienceDirect

(Clinicians and GeneReviews emphasize UMOD and MUC1 as the most frequent, with others less common.) OUP Academic+1

Causes

Important note: The root cause of ADTKD is a disease-causing variant in one of the genes above. The items below group the genetic causes by gene and then list common real-world aggravators that can speed loss of kidney function. I’m labeling which are genetic and which are aggravating factors to keep things accurate.

Genetic causes (primary):

1. UMOD variants (uromodulin protein misfolding and buildup in tubular cells). Leads to early hyperuricemia and gout. PMC

2. MUC1 variants (toxic MUC1 frameshift protein accumulates in tubular cells). NCBI

3. REN variants (renin pathway changes; early anemia, low blood pressure, salt-wasting). PubMed

4. HNF1B variants (transcription factor affecting kidney development and function; extra-renal features possible). OUP Academic

5. SEC61A1 variants (protein-translocation channel defects; rare). OUP Academic

6. DNAJB11 variants (chaperone protein; “atypical” ADTKD with cystic overlap). OUP Academic

7. APOA4 variants (rare; emerging evidence from families). ScienceDirect

Aggravating or progression-accelerating factors (secondary):

1. Repeated dehydration (concentrated urine stresses tubules).
2. High dietary sodium (can worsen CKD and blood pressure control).
3. Uncontrolled high blood pressure (speeds CKD decline).
4. Frequent NSAID use (e.g., ibuprofen, diclofenac; reduces prostaglandin-mediated renal blood flow).
5. Episodes of acute kidney injury (any cause) on a background of ADTKD.
6. Poorly controlled diabetes (especially in HNF1B families with diabetes).
7. Recurrent urinary infections (interstitial inflammation may add scarring).
8. Chronic hyperuricemia/gout flares (correlates with UMOD disease; control may reduce attacks). MedlinePlus
9. High-protein or crash ketogenic diets without medical guidance (osmotic load can stress tubules).
10. Smoking (vascular harm may accelerate CKD).
11. Nephrotoxic antibiotics when avoidable (e.g., aminoglycosides).
12. Contrast dye without precautions (iodinated contrast can trigger AKI in CKD).
13. Lack of routine CKD care (no BP, uric acid, bicarbonate, and CKD metabolic bone checks).

Common symptoms and signs

1. Tiredness and low energy because waste builds up as kidneys weaken.

2. Slow, steady rise in creatinine over years (often found on routine blood tests).

3. Uric acid is high early in life in UMOD type; this can be silent at first. PMC

4. Gout attacks (painful, red, swollen joints; often in late teens or young adults in UMOD). MedlinePlus

5. More urination at night (nocturia) because kidneys lose concentrating ability.

6. Passing a lot of dilute urine and feeling thirst.

7. Mild or no protein in urine and little or no blood in urine (“bland” urinalysis). ScienceDirect

8. High blood pressure in some people as CKD advances.

9. Cramping or muscle weakness if potassium or bicarbonate are off balance.

10. Anemia, especially in REN-related disease or later CKD. PubMed

11. Kidney cysts may appear in some types (more with HNF1B). OUP Academic

12. Salt-wasting and dizziness in REN-related type, especially during illness or heat. PubMed

13. Poor growth or failure to thrive in children with certain types (notably REN). PubMed

14. Family history of CKD, gout, or kidney failure across generations. Kireports

15. Few or no kidney-related pains (pain is not a dominant feature; disease is often silent for years). ScienceDirect

Diagnostic tests

I’ve grouped tests by category and included what each tells the clinician.

A) Physical examination

1. Blood pressure check – high BP is common as CKD progresses and must be treated to slow decline.

2. Hydration status – dry mouth, low skin turgor, or dizziness can hint at salt-wasting (REN type) or dehydration. PubMed

3. Joint examination – warmth, redness, tenderness suggest gout (UMOD type). MedlinePlus

4. Weight and growth in children – screens for failure to thrive (more likely in REN families). PubMed

5. Look for extra-renal features – e.g., signs of diabetes or developmental differences in HNF1B families. OUP Academic

B) “Manual” or bedside tests

6. Urinalysis with dipstick and microscopy – often bland (little protein, little blood). This pattern points toward tubulointerstitial disease rather than classic glomerular diseases. ScienceDirect

7. Spot urine specific gravity or osmolality – low concentrating ability suggests tubular injury.

8. 24-hour or timed urine for uric acid – helps calculate fractional excretion of urate (FEurate), which is often reduced in UMOD disease. PMC

9. Ambulatory/home BP monitoring – documents sustained hypertension and guides therapy.

10. Diet and medication review – identifies NSAIDs or other nephrotoxins that can be stopped.

C) Laboratory and pathological tests

11. Serum creatinine and eGFR – track kidney function over time (the key trend in ADTKD). Kireports

12. Serum uric acid – high early in UMOD; supports the clinical picture with gout. MedlinePlus

13. Electrolytes and bicarbonate – detects metabolic acidosis, potassium problems, or salt-wasting states (REN). PubMed

14. Hemoglobin and iron studies – check for anemia (can be early in REN or later in CKD). PubMed

15. Albumin-to-creatinine ratio – usually low or normal in ADTKD compared with many glomerular diseases. ScienceDirect

16. Genetic testing panel for UMOD, MUC1, REN, HNF1B, SEC61A1, DNAJB11, and others – this is the most definitive diagnostic test for ADTKD; it confirms the exact type and supports family screening. rarekidney.org

17. Kidney biopsy – often not helpful in ADTKD because changes are non-specific; guidelines and expert groups emphasize genetics over biopsy for diagnosis. rarekidney.org

D) Electrodiagnostic and physiologic tests

18. Electrocardiogram (ECG) – not to diagnose ADTKD itself, but to detect CKD-related heart rhythm changes (e.g., hyperkalemia effects) and guide urgent care.

19. 24-hour ambulatory BP monitoring – classed here as a physiologic recording to capture true BP load and dipping pattern in CKD.

E) Imaging tests

20. Renal ultrasound – kidney size can be normal or small; cysts may be present in some subtypes (more often HNF1B). Ultrasound mainly rules out other causes; it cannot by itself diagnose ADTKD. OUP Academic

21. Non-contrast CT or MRI – rarely needed for diagnosis; used if complications or other diagnoses are suspected (stones, obstruction, atypical cysts).

22. Targeted imaging for family members – may look normal early; imaging does not replace genetics when ADTKD is suspected. Definitive testing is genetic.

Non-pharmacological treatments (therapies & others)

1) Education about the disease and genes.
Learning the subtype (UMOD, MUC1, REN, HNF1B) helps you and your family plan testing and follow-up. Knowing it is autosomal dominant (50% risk to children) supports family screening and early CKD care. Kidney transplant is curative and does not usually see disease recurrence. NCBI

2) Blood pressure control with lifestyle.
Aim for healthy weight, regular walking, and salt reduction. Good blood pressure slows CKD in all causes, including ADTKD. KDIGO emphasizes BP control as a key renal-protection strategy. KDIGO

3) Sodium restriction.
Limit added salt and high-sodium processed foods to help BP and reduce kidney stress. This is a standard CKD measure in KDIGO guidance. KDIGO

4) Adequate hydration (avoid dehydration).
Steady fluid intake prevents pre-renal kidney stress and may help gout by lowering uric acid concentration; avoid extremes (over-drinking) unless your clinician advises otherwise. GeneReviews encourages staying in optimal health for transplant planning. NCBI

5) “Sick-day” rules.
During vomiting/diarrhea or fever, temporarily stop medicines that strain kidneys (only if your clinician has taught you which ones), and re-start when well. This principle is embedded in CKD safety practices in guidelines. KDIGO

6) Avoid NSAIDs unless directed.
Non-steroidal anti-inflammatory drugs can reduce blood flow in the kidneys and worsen CKD. Use safer pain plans with your clinician. KDIGO lists nephrotoxin avoidance as core care. KDIGO

7) Contrast-sparing imaging.
If scans are needed, ask about non-contrast options or kidney-friendly protocols. This is standard CKD risk reduction in guidelines. KDIGO

8) Smoking cessation.
Stopping smoking improves blood pressure, heart health, and kidney outcomes. KDIGO highlights cardiovascular risk management in CKD. KDIGO

9) Heart-healthy eating pattern.
Focus on vegetables, fruits, whole grains, and lean proteins, while adjusting potassium/phosphorus as kidney function falls (per dietitian). KDIGO supports individualized nutrition to meet CKD stages. KDIGO

10) Protein intake tailored to stage.
Moderate protein intake may help slow CKD; dietitians adjust amounts by eGFR and nutrition status (avoid malnutrition). KDIGO provides protein guidance by CKD stage. KDIGO

11) Weight management.
Healthy weight lowers BP and cardiovascular risk. This is part of “optimal health” planning emphasized for transplant readiness. NCBI

12) Regular exercise.
Aim for most days of the week with light-to-moderate activity to improve BP and energy. Physical activity is a general CKD protective measure. KDIGO

13) Vaccination updates.
Stay current with vaccines recommended for CKD (e.g., influenza, hepatitis B as appropriate) to reduce infection risk. This is routine CKD care. KDIGO

14) Anemia monitoring and iron/nutrition planning.
Regular checks of hemoglobin and iron decrease fatigue and guide therapy. GeneReviews notes anemia management within CKD care. NCBI

15) Mineral-bone disease monitoring.
Track calcium, phosphorus, PTH, and vitamin D; nutrition and meds are adjusted to protect bones and vessels. KDIGO outlines CKD-MBD care. KDIGO

16) Gout self-management (if affected).
Identify triggers, hydrate, avoid binge alcohol and high-purine foods; discuss urate-lowering plans if attacks recur. ACR’s 2020 gout guideline explains modern urate-lowering strategies. Acr Journals

17) Genetic counseling for family planning.
Explain 50% inheritance risk and options for testing relatives and potential donors. GeneReviews gives step-by-step guidance. NCBI

18) Early transplant education.
Ask early about transplant pathways because ADTKD does not recur in the graft, and outcomes are excellent. GeneReviews stresses early preparation. NCBI

19) Medication review at every visit.
Bring all meds and supplements to avoid harmful overlaps and to adjust doses as eGFR changes. KDIGO calls for regular medication safety checks. KDIGO

20) Reliable follow-up plan.
Schedule labs and visits based on CKD stage (more frequent as eGFR falls) to act early on BP, anemia, acidosis, or potassium changes. KDIGO provides stage-based follow-up intensity. KDIGO

---

Drug treatments

Important: The medicines below treat CKD complications (BP, potassium, phosphorus, anemia) and gout where relevant. There is no single drug that “cures” ADTKD; transplant is the definitive therapy when kidneys fail. Always individualize doses to eGFR and your clinician’s advice.

1) Allopurinol (xanthine-oxidase inhibitor) — gout/urate control.
Class: Uric acid–lowering. Typical adult start is 100 mg daily and titrate; start lower (e.g., 50 mg daily) in CKD and raise slowly to target serum urate <6 mg/dL while watching for rash or rare severe reactions. Time: once daily with dose titration weekly/biweekly. Purpose: prevent flares and tophi by lowering uric acid production. Mechanism: blocks xanthine oxidase to reduce uric acid creation. Side effects: rash, rare severe skin reactions, liver test changes; dose adjustment in renal impairment. FDA Access Data

2) Febuxostat (ULORIC) — alternative XO inhibitor (use with caution).
Class: Uric acid–lowering. Dose: 40–80 mg once daily (per label), no adjustment for mild/moderate renal impairment; discuss CV risk warning. Time: daily. Purpose: lower uric acid if allopurinol not tolerated/ineffective. Mechanism: non-purine XO inhibition. Side effects: liver enzyme rises; boxed cardiovascular warnings have applied; follow current label and clinician guidance. FDA Access Data+1

3) Colchicine — gout flare prevention/treatment (dose-adjust in CKD, avoid drug interactions).
Class: Anti-inflammatory for gout. Dosing: per brand labeling (for example, Mitigare 0.6 mg capsules) with caution in renal impairment and strong CYP3A4/P-gp interactions. Purpose: prevent or treat flares during urate-lowering initiation. Mechanism: reduces neutrophil activity in crystals. Side effects: GI upset, myopathy risk with certain drugs. FDA Access Data

4) Dapagliflozin (FARXIGA) — SGLT2 inhibitor for CKD risk reduction (diabetic or non-diabetic CKD).
Class: SGLT2 inhibitor. Dose: commonly 10 mg once daily (see label). Purpose: reduce risk of sustained eGFR decline, kidney failure, CV death, and HF hospitalization in adults with CKD at risk of progression. Mechanism: promotes urinary glucose/sodium excretion; kidney hemodynamic benefits. Side effects: genital infections, volume depletion; AKI has been reported—monitor. FDA Access Data+1

5) Losartan — ARB for BP/albuminuria (when present).
Class: Angiotensin receptor blocker. Dose: individualized (e.g., 50–100 mg daily). Purpose: lower BP and slow kidney scarring when proteinuria is present; indicated for diabetic nephropathy in label. Mechanism: blocks angiotensin II effects. Side effects: high potassium, kidney function changes; avoid in pregnancy. FDA Access Data

6) Lisinopril — ACE inhibitor for BP/renal protection (proteinuric states).
Class: ACE inhibitor. Dose: titrate from low dose; adjust by BP and kidney labs. Purpose: BP control and proteinuria reduction in CKD when indicated. Mechanism: blocks angiotensin-converting enzyme. Side effects: cough, hyperkalemia, kidney function changes; contraindicated in pregnancy. FDA Access Data

7) Furosemide — loop diuretic for edema and BP.
Class: Loop diuretic. Dose: individualized; powerful diuresis requires careful monitoring of electrolytes. Purpose: control swelling and help BP. Mechanism: blocks sodium reabsorption in loop of Henle. Side effects: low potassium/magnesium, dehydration, ototoxicity at high doses; dosing caution is essential. FDA Access Data+1

8) Sevelamer carbonate (Renvela) — phosphate binder in dialysis CKD.
Class: Non-calcium phosphate binder. Dose: with meals; titrate to phosphorus targets. Purpose: control high phosphorus and protect bones/vessels in dialysis CKD. Mechanism: binds phosphate in the gut. Side effects: GI upset (nausea, constipation/diarrhea). FDA Access Data

9) Calcitriol / Paricalcitol (active vitamin D) — CKD-MBD control.
Class: Vitamin D analogs. Dose: per label and PTH targets (paricalcitol capsules or injection have stage-specific indications). Purpose: reduce secondary hyperparathyroidism. Mechanism: activates vitamin D receptor to suppress PTH. Side effects: high calcium/phosphorus—monitor closely. FDA Access Data+1

10) Epoetin alfa (Epogen/Procrit) — anemia of CKD.
Class: ESA. Dose: weight-based; adjust to hemoglobin targets; monitor for PRCA risk and cardiovascular events. Purpose: raise hemoglobin and reduce transfusions. Mechanism: erythropoietin analog stimulates red cell production. Side effects: hypertension, thrombosis risk; use lowest dose to avoid transfusions. FDA Access Data+1

11) Darbepoetin alfa (Aranesp) — longer-acting ESA.
Class: ESA. Dose: every 1–2 weeks or per label; titrate to hemoglobin goals. Purpose: treat CKD anemia similarly to epoetin. Mechanism: engineered erythropoiesis stimulator. Side effects: hypertension, thrombotic risk; label notes oncology safety context; follow CKD dosing. FDA Access Data+1

12) IV iron sucrose (Venofer) — iron repletion in CKD.
Class: Parenteral iron. Dose: per protocol (e.g., 100–200 mg per dose IV to cumulative iron requirement). Purpose: treat iron deficiency and support ESA response. Mechanism: supplies iron for hemoglobin synthesis. Side effects: infusion reactions, hypotension—monitor during IV administration. FDA Access Data

13) Patiromer (Veltassa) — chronic hyperkalemia control.
Class: Potassium binder. Dose: 8.4 g once daily, titrate; separate from other oral meds. Purpose: lower high potassium so ACEi/ARB therapy can continue when appropriate. Mechanism: binds potassium in the gut. Side effects: constipation, low magnesium; check interactions. FDA Access Data+1

14) Sodium zirconium cyclosilicate (Lokelma) — hyperkalemia control.
Class: Potassium binder. Dose: 10 g three times daily up to 48 hours, then maintenance (e.g., 10 g daily). Purpose: maintain normal potassium in CKD. Mechanism: exchanges sodium/hydrogen for potassium in the gut. Side effects: edema; not for emergency life-threatening hyperkalemia. FDA Access Data+1

15) Sodium bicarbonate (oral) — treat metabolic acidosis in later CKD.
Class: Alkali therapy. Dose: individualized tablets/powder to correct low serum bicarbonate. Purpose: correct acidosis to protect muscle and bone and possibly slow CKD. Mechanism: buffers acid load. Side effects: edema, hypertension if sodium load exceeds plan—monitor closely. (Label examples exist for sodium bicarbonate products; dosing strategy is guided by CKD care standards.) NCTR CRS+1

16) Statins (e.g., atorvastatin) — cardiovascular risk reduction (when indicated).
Class: HMG-CoA reductase inhibitors. Dose: per dyslipidemia guideline and renal function. Purpose: lower cardiovascular events, a major risk in CKD. Mechanism: reduces LDL. Side effects: myopathy, liver enzyme elevations; check interactions. (Use per CKD guidelines; specific labels vary.) KDIGO

17) Loop/thiazide-type diuretic combinations (advanced CKD edema/BP).
Class: Diuretics. Purpose: control fluid and BP when one agent is inadequate (clinician-directed). Mechanism: sequential nephron blockade. Side effects: electrolyte shifts; careful monitoring per CKD practice. KDIGO

18) Antihypertensive add-ons (calcium-channel blockers, beta-blockers) as needed for BP targets.
Class: BP agents. Purpose: reach guideline BP goals when ACEi/ARB alone is not enough. Mechanism/SE: class-specific; individualized by comorbidity. KDIGO

19) Vitamin D (nutritional) supplementation for deficiency.
Class: Nutritional D. Purpose: correct deficiency alongside CKD-MBD care (distinct from active vitamin D analogs). Mechanism: raises 25(OH)D; detailed dosing per labs and guideline. KDIGO

20) Low-dose aspirin for cardiovascular protection (select patients after clinician review).
Class: Antiplatelet. Purpose: reduce CV events in appropriate risk profiles. Mechanism: COX-1 inhibition reduces platelet aggregation; balance bleeding risks per guidelines. KDIGO

---

Dietary molecular supplements

Note: Supplements can interact with prescription drugs and may be unsafe in CKD. Always ask your clinician/dietitian; use lab-guided plans from CKD guidelines.

1) Vitamin D (cholecalciferol/ergocalciferol) for deficiency. Helps bone and PTH balance when low; dosing is lab-guided in CKD. This complements, not replaces, active vitamin D analogs when indicated. KDIGO

2) Omega-3 fatty acids (fish oil) for triglycerides and possible anti-inflammatory benefit; use CKD-safe doses and watch bleeding risk. Evidence is mixed; personalize with your clinician. KDIGO

3) Oral iron (when not using IV iron) to treat iron deficiency; absorption is limited in some CKD patients; IV iron is often preferred when oral fails. KDIGO

4) Vitamin B12 and folate (if deficient) to support red blood cell production; treat confirmed deficiencies rather than “routine” use. KDIGO

5) Calcium (with caution) only when diet is insufficient and phosphorus/calcium balance allows; excess calcium can raise vascular calcification risk in CKD—follow labs. KDIGO

6) Sodium bicarbonate powder/tablets (as “supplement-form alkali”) to correct low serum bicarbonate in CKD; dose and monitoring are medical decisions. NCTR CRS+1

7) Water-soluble multivitamin (renal-adjusted) if diet is limited by CKD restrictions; avoid high vitamin A/K. Use products designed for CKD under guidance. KDIGO

8) Protein supplements (renal-safe formulas) if clinically malnourished; otherwise avoid excess protein; dietitian sets targets. KDIGO

9) Magnesium (with caution) only if low and if potassium and kidney function allow; hypermagnesemia can occur in CKD—lab-driven. KDIGO

10) Probiotics (adjunctive) have limited, evolving data in CKD; if used, choose reputable brands and inform your clinician. Evidence remains inconclusive; prioritize proven CKD measures first. KDIGO

---

Immunity-booster / regenerative / stem-cell drugs

I need to be very clear and safe here: there are no FDA-approved stem-cell or “regenerative” drugs for treating kidney failure or ADTKD, and the FDA actively warns consumers about unapproved stem-cell products and clinics. The only FDA-approved stem-cell products are blood-forming stem cells from umbilical cord blood for specific hematologic disorders, not kidney disease. So I cannot list six such drugs for ADTKD, because they do not exist and it would be unsafe and misleading. If you see offers online for stem-cell “cures” for CKD/ADTKD, the FDA warns these are unapproved and potentially harmful. U.S. Food and Drug Administration+1

Safer alternatives are the evidence-based CKD measures and transplant preparation described above. If you’d like, I can summarize ongoing research areas (preclinical/early clinical) without suggesting unapproved therapies. KDIGO

---

Procedures/surgeries

1) Arteriovenous fistula (AVF) creation for hemodialysis.
A surgeon connects an artery to a vein (usually in the arm) to make a strong access for dialysis needles. Why: AVFs have the best long-term patency and lowest infection risk among hemodialysis accesses. This is standard ESRD planning in CKD care. KDIGO

2) Peritoneal dialysis catheter placement.
A soft tube is placed into the abdomen to let dialysate flow in and out at home. Why: allows peritoneal dialysis, which some patients prefer for flexibility and steady fluid removal. Choice depends on lifestyle and medical factors. KDIGO

3) Kidney transplant.
A healthy donor kidney is placed surgically, and you take immune-suppression drugs afterward. Why: ADTKD does not recur in the transplanted kidney, and outcomes are excellent, making transplant the definitive treatment. NCBI

4) Kidney biopsy (select cases).
A needle sample of kidney tissue is taken to look under the microscope. Why: sometimes used when diagnosis is unclear; in ADTKD, biopsy is often nonspecific, and genetic testing is preferred. NCBI

5) Dialysis catheter (temporary) or graft (when AVF not feasible).
Why: provide dialysis access if time is short or veins are unsuitable; long-term plan often aims for AVF when possible. KDIGO

---

Preventions

1. Keep blood pressure in target range set by your clinician; this slows CKD. KDIGO

2. Reduce dietary salt to help BP and swelling. KDIGO

3. Stay hydrated, especially in hot weather or illness (but avoid over-hydration). KDIGO

4. Avoid NSAIDs and other nephrotoxins unless your clinician approves. KDIGO

5. Tell imaging teams you have CKD; use contrast-sparing options. KDIGO

6. Keep vaccines up to date to reduce infection-related kidney hits. KDIGO

7. Manage anemia, phosphorus, and vitamin D per labs to protect bones and heart. KDIGO

8. If you have gout, follow a treat-to-target urate plan to prevent flares. Acr Journals

9. Stop smoking; it improves kidney and heart outcomes. KDIGO

10. Arrange regular follow-ups and lab checks matched to your CKD stage. KDIGO

---

When to see a doctor

See your kidney team promptly for new swelling, severe fatigue, rapid BP rise, reduced urine, frequent gout flares, or side effects after a medicine change. Seek urgent care for chest pain, shortness of breath, confusion, very high potassium symptoms (weakness, palpitations), or severe dehydration. Regular follow-up is essential as eGFR declines. These triggers are consistent with standard CKD safety guidance and gout care pathways. KDIGO+1

---

What to eat  — and what to avoid

Eat more of:

1. Fresh vegetables and fruits in amounts that fit your potassium allowance. KDIGO
2. Whole grains and high-fiber foods for heart health. KDIGO
3. Lean proteins (fish, poultry, plant proteins) in portion sizes your dietitian sets. KDIGO
4. Healthy fats (olive oil, nuts in moderation if potassium permits). KDIGO
5. Enough water across the day unless your clinician sets a fluid limit. KDIGO

Limit/avoid:

1. High-salt foods (chips, instant noodles, processed meats). KDIGO
2. Excess animal protein if your dietitian sets a moderate target. KDIGO
3. High-purine foods (organ meats, anchovies) if you get gout. Acr Journals
4. Alcohol binges, which can trigger gout and harm kidney and heart health. Acr Journals
5. Herbal supplements without approval—some are nephrotoxic or interact with meds. KDIGO

---

Frequently asked questions

1) Is ADTKD the same as “medullary cystic kidney disease”?
Old names overlapped. Today, ADTKD is the preferred term; medullary cysts are not required for diagnosis. NCBI

2) Which genes cause ADTKD?
Most often UMOD or MUC1; less often REN, HNF1B, SEC61A1, DNAJB11. Genetic testing confirms the subtype. OUP Academic

3) Does everyone get gout?
No. Gout is common in UMOD and may appear young, but not all patients get it; in MUC1, gout relates to later CKD. NCBI

4) Can medicines stop ADTKD?
There is no cure medicine yet. We treat CKD complications well and prepare for transplant if kidneys fail. KDIGO

5) Will the disease come back after a transplant?
ADTKD does not recur in the transplanted kidney, and outcomes are excellent. NCBI

6) How fast will my kidneys decline?
Progression varies widely—even within families. Regular monitoring guides timing for access or transplant planning. NCBI

7) Should my family be tested?
Yes—autosomal-dominant inheritance means a 50% chance to pass it on. Genetic counseling is recommended. NCBI

8) What BP is “good” for kidney protection?
Your clinician sets a target using KDIGO CKD guidance; lower salt and the right meds help reach it. KDIGO

9) Are SGLT2 inhibitors for me if I don’t have diabetes?
Dapagliflozin has a CKD indication to reduce kidney and heart risks in adults with CKD at risk of progression, regardless of diabetes status; your team will check eGFR and safety. FDA Access Data

10) How do we prevent gout flares when starting urate-lowering therapy?
Use prophylaxis (e.g., low-dose colchicine, adjusted for CKD) and a treat-to-target urate plan per ACR 2020 guideline. Acr Journals

11) Are NSAIDs safe for gout if I have CKD?
Often no; NSAIDs can harm kidneys. Discuss safer anti-inflammatory options with your clinician. KDIGO

12) Do I need phosphate binders or vitamin D analogs now?
Only if labs show CKD-MBD issues; therapy is personalized and monitored. FDA Access Data+1

13) Is there an “immune booster” or stem-cell drug for ADTKD?
No FDA-approved stem-cell or regenerative drugs treat CKD/ADTKD; beware unapproved clinics. U.S. Food and Drug Administration

14) Can I be a kidney donor for a relative if ADTKD runs in my family?
Potential related donors should have genetic testing first to ensure they do not carry the familial variant. NCBI

15) What’s the most important thing I can do today?
Know your subtype (if possible), control BP and salt, review meds for kidney safety, and keep regular CKD follow-ups. KDIGO

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 03, 2025.